74 related articles for article (PubMed ID: 38489142)
1. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
3. Non-tumor-related prognostic factors for immunotherapy-chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC).
Guo Z; Wei X; Tang C; Liang J
Clin Exp Med; 2024 Mar; 24(1):52. PubMed ID: 38489142
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
6. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
9. The preoperative hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for non-small cell lung cancer patients undergoing adjuvant chemotherapy: a retrospective study.
Wei S; Shao J; Wang J; Wang G
Ann Transl Med; 2022 Apr; 10(8):457. PubMed ID: 35571436
[TBL] [Abstract][Full Text] [Related]
10. Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.
Wang L; Zhang H; Pan C; Yi J; Cui X; Li N; Wang J; Gao Z; Wu D; Chen J; Jiang J; Chu Q
Front Immunol; 2022; 13():829634. PubMed ID: 35529874
[TBL] [Abstract][Full Text] [Related]
11. Nomogram based on prognostic nutrition index and Chest CT imaging signs predicts lymph node metastasis in NSCLC patients.
Chen M; Yang Y; He C; Chen L; Cheng J
J Xray Sci Technol; 2022; 30(3):599-612. PubMed ID: 35311733
[TBL] [Abstract][Full Text] [Related]
12. Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Bureau M; Chatellier T; Perennec T; Goronflot T; Greilsamer C; Chene AL; Affi R; Frampas E; Bennouna J; Pons-Tostivint E
Cancer Immunol Immunother; 2022 Jul; 71(7):1747-1756. PubMed ID: 34839373
[TBL] [Abstract][Full Text] [Related]
13. Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.
Patel KK; Kashfi K
Biochem Pharmacol; 2022 Feb; 196():114654. PubMed ID: 34129857
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy.
Guo Z; Liang J
Cancer Manag Res; 2021; 13():4169-4180. PubMed ID: 34079370
[TBL] [Abstract][Full Text] [Related]
15. Construction of a prognostic model for non-small-cell lung cancer based on ferroptosis-related genes.
Han K; Wang J; Qian K; Zhao T; Liu X; Zhang Y
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988228
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
